Feeds:
Posts
Comments

Archive for the ‘BioTechnology – Venture Creation, Venture Capital’ Category


Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

is pleased to announce its sponsorship and invite you to attend

The New England Venture Summit presented by youngStartup Ventures.

@pharma_BI

@AVIVA1950

 #NEVS

Agenda

●●●

Wednesday, December 4th, 2019

8:00 am

CONFERENCE REGISTRATION & CONTINENTAL BREAKFAST

8:50 am

WELCOME REMARKS

9:00 am

THE CHANGING VENTURE WORLD: WHAT CAN WE EXPECT FOR THE NEXT 24 MONTHS?

Venture Capital thought leaders debate the challenges and opportunities facing Investors and Entrepreneurs

Location: Fairbanks Ballroom

9:50 am

BREAK

10:00 am

COMPANY PRESENTATIONS – ROUND I

Track I:   Technology (Charles W. Fairbanks Ballroom)
Track II:  Life Sciences/Healthcare (Grace Ballroom)
Track III: Cleantech (New England Suite)
Track IV: Fintech (Westwood Suite)
Track V:  Seed Pitchfest (Erastus C. Fairbanks Ballroom)

11:00 am

NETWORKING & REFRESHMENT BREAK

11:40 am

COMPANY PRESENTATIONS – ROUND II

Track I:   Technology (Charles W. Fairbanks Ballroom)
Track II:  Life Sciences/Healthcare (Grace Ballroom)
Track III: Cleantech (New England Suite)
Track IV: Fintech (Westwood Suite)
Track V:  Seed Pitchfest (Erastus C. Fairbanks Ballroom)

12:50 pm

LUNCH & NETWORKING (12:50pm – 1:50pm)

Please see below for information on concurrent session running throughout lunch.

1:00 pm

RAISING ANGEL MONEY – INFO & INSIGHTS FROM SEASONED INVESTORS

Location: Grace Ballroom

1:50 pm

COMPANY PRESENTATIONS – ROUND III

Track I:   Technology (Charles W. Fairbanks Ballroom)
Track II:  Life Sciences/Healthcare (Grace Ballroom)
Track III: Cleantech (New England Suite)
Track IV: Fintech (Westwood Suite)
Track V:  Seed Pitchfest (Erastus C. Fairbanks Ballroom)

3:00 pm

CONCURRENT PANELS:

THE ART OF NEGOTIATING TERMS SHEETS

Entrepreneurs who don’t prepare well for term-sheet negotiations may find themselves locked into an uncomfortable relationship with their VC for years to come.  Whether you’re looking for a first-round or follow-up funding, attend this panel to learn what you should know about negotiating term sheets.

Location: Fairbanks Ballroom

ENERGIZING THE FLOW OF CLEAN-TECH DEALS

This session will discuss the trends in the financial markets and the future of venture capital investment in clean-tech.

Location: Grace Ballroom

BANKING ON FIN-TECH INNOVATION

Join top-tier VCs to discuss the rise of fintech, the integration of groundbreaking technologies within financial services, and the future of digital finance.

Location: New England Suite

3:50 pm

NETWORKING & REFRESHMENT BREAK

4:30 pm

CONCURRENT PANELS:

FUNDABLE DEALS: MAKING VCs SIT UP AND TAKE NOTICE

Ideas are all well and good, but in order to attract capital they will need to be packaged and presented in a way that will entice investors and of course a SOLID business model.  This panel will discuss the skills required to make a highly effective pitch that will attract potential financiers and the types of deals investors want.

Location: Grace Ballroom

 

CORPORATE VENTURE CAPITAL: WHAT YOU NEED TO KNOW

With a new flowering of startup innovation, many giants of industry have decided to enter or re-enter the world of VC. This session will explore the value-added investment approach of Corporate VCs and how it yields important dividends that are “beyond the bottom line,” both for the investor and for the startup.

Location: Fairbanks Ballroom

LIFE SCIENCES & HEALTHCARE VC CHECKUP

VCs compare and contrast the growth of seemingly healthy companies. What did these companies do right? Where did they go wrong? Which one would be considered a healthier investment and why? Does your company measure up? What healthy habits will make your company a more desirable investment? Find out if you pass the VC health checkup.

Location: New England Suite

5:20 pm

AWARDS & CLOSING REMARKS

5:30 pm

SUMMIT ADJOURNS

UPDATED on 11/25/2019

 

Last chance to register for The New England Venture Summit presented by youngStartup Ventures.

Special discount.  Use discount code LPBI-VIP” and receive $100 off the current rates

 

>> Call for Top Innovators to present to leading Investors (details below).

 

New England

Venture Summit

December 4th 2019 | Hilton | Boston, Dedham

 

Where Innovation Meets Capital

 

 

Friends,

 

Come meet, interact and network with hundreds of VCs, Corporate VCs, angel investors, investment bankers and founders of venture backed, emerging and early stage companies on the Lifesciences/Healthcare Track at the prestigious New England Venture Summit being held on December 4th 2019 at the Hilton in Boston, Dedham.

 

Whether you’re a Lifescience/Healthcare startup seeking capital and exposure, or a Biotech investor seeking new deals, The New England Venture Summit presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, the Lifesciences/Healthcare track at The New England Venture Summit is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

 

Partial List of over 150 VCs & Angel Investors confirmed to speak and judge includes:Anil Achyuta, Investment Director, TDK Ventures | Omair Ahmed, Associate, Echo Health Ventures | Navneet Alag, Vice President, H.I.G. BioHealth Partners | Dave Anderson, Managing General Partner, Supply Chain Ventures | Mark Austin, Managing Director, Viridian Capital | Shannon Austin, Partner, Financial Venture Studio | Natalie Bartlett, Investor, General Catalyst | Anna Batarina, Partner, Apple Tree Partners | Kyle Beatty, Principal, American Family Ventures | Anthony Bellafiore, Associate, LaunchCapital | Ned Berman, Senior Associate, Samsung Catalyst Fund | Matt Bloom, Investment Director, Connecticut Innovations | Carsten Boers, Managing Partner, Rhapsody Venture Partners | Greg Bohlen, Managing Director, Union Grove Venture Partners | Caitlin Bolnick, Investor, OpenView Venture Partners | Lee Bouyea, Managing Director, Fresh Tracks Capital | Maureen Boyce, Managing Partner, Good Growth Capital | Eric Breese, Investment Manager, Evonik Venture Capital | Nathaniel Brinn, Partner, VC23 Investors | Brendan Brits, Investor, Bertelsmann Digital Media Investments | Peter Bruce-Clark, Partner, Social Impact Capital | Ciara Burnham, Partner, QED Investors | Daniel Burstein, Managing Partner, Millennium Technology Value Partners | Jeffrey Carter, General Partner, West Loop Ventures | Kathryn Cartini, Partner, Chloe Capital | Anup Chamrajnagar, Investor, Point72 Ventures | Sean Cheng, Investment Manager, Philips Ventures | Ian Chiang, Principal, Flare Capital Partners | Elizabeth Cho-Fertikh, Co-Founder & Managing Director, MEDA Angels | Andrew Clapp, Managing Director, CIG CAP | Iain Cooper, Manager Corporate Ventures, Schlumberger Technology Investments | Mark Cupta, Partner, Prelude Ventures | John Curtin, Associate, Waterline Ventures | Kapil Desai, Vice President, Catalyst Investors | Damien Despinoy, Director, Energy Foundry | Dan Doble, Managing Director, SABIC Ventures | Lisa Dolan, Principal, Link Ventures | Tyler Durham, Principal, Schlumberger Technology Investments | Laura Easton, Analyst, Real Ventures | Jonathan Friedlander, Principal, Digitalis Ventures | Lisa Frusztajer, Lead Investor, Portfolia Enterprise Fund | Ernestine Fu, Venture Partner, Alsop Louie Partners | Stan Fung, Managing Director, FarSight Ventures | Robert Garber, Partner, 7wire Ventures | Stephen Gilfus, Founder, Blackboard Inc. | Elianna Goldstein, Analyst, Boeing HorizonX Ventures | Alex Golod, Angel Investor, Chicago ArchAngels | Emilia Gonzalez, Principal, Joyance Ventures | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | Edward Greer, Corporate Technology Scout, Dow Ventures | Vicky Guo, Investment Director, Pearson Ventures | Robert Hamlin, Principal, Portag3 Ventures | Jana Hanova, Director, Evok Innovations | Sven Harmsen, Director External Ventures, NOVA External Ventures Saint-Gobain | Andrew Hartford, Managing Partner, Hartford Lab | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Kaitlyn Henry, Associate, OpenView Venture Partners | Chris Ho, Vice President, Vickers Venture Partners | Toan Huynh, Partner, Information Venture Partners | Ben Jen, CEO & Angel Investor, Ben Jen Holdings LLC | Del Johnson, Principal, Backstage Capital | Jay Karandikar, Venture Partner, New Crop Capital | Madeline Keulen, Vice President, Victress Capital | Roman Kikta, Managing Partner & Founder, Mobility Ventures | Frank Klemens, Managing Director, DuPont Ventures | Jak Knowles, Vice President Venture Investments, Leaps by Bayer | Diana Kontsevaia, Investor, Dell Technologies Capital | Ventures | Luda Kopeikina, Investment Director, DSM Venturing | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Ed Lafferty, Partner & CFO, Saturn Partners | Logan Langberg, Principal, Imaginary Ventures | Tiffany Le, Investor, Kaiser Permanente Ventures | James Lee, Investment Associate Director, Photon Fund | Claire Leurent, Managing Director, Samsung Ventures | Debbie Lin, Executive Director & Investment Manager, Boehringer Ingelheim Venture Fund | Darwin Ling, Founding General Partner, Good AI Capital | Jim Lockheed, Investment Associate, JetBlue Technology Ventures | Mary Long-Irwin, Executive Director, Northern Ontario Angels | Bion Ludwig, Partner, Savano Capital Partners | Josh Lumer, Senior Associate, Allstate Strategic Ventures | Alan MacIntosh, General Partner, Real Ventures | Wasim Malik, Managing Partner, Iaso Ventures | Ricky Margolis, VP of Business Development, ARIE Capital | Hollis McGuire, Director, Impact NH Fund | Theo Mendez, Investor, Insight Partners | Philip Mertens, Investment Analyst, DSM Venturing | Sarah Millar, Associate, City Light Capital | David Miller, Co-Founder and Managing Director, Clean Energy Ventures | Mark Miller, Managing Partner, Good Harbor Partners | Yiannis Monovoukas, Co-Founder & Managing Partner, SpringTide Ventures | Craig Mullett, Director, Angel Investor Forum | Jared Newman, Associate, Betawork Ventures | Clay Norris, Investment Associate, Carolinas Fintech Ventures | Michael Pachos, Head of East Coast / Managing Director, Samsung Ventures | Akhilesh Pathipati, Principal, MVM Partners | Charles Paul, Vice President – Technology, Henkel Ventures | Caroline Pelletier, Angel Investor, Anges Québec | Mike Perry, Investment Associate, Link Ventures | Damien Petty, Principal, Morpheus Ventures | Lauren Michelle Pfeifer, Principal, Maschmeyer Group Ventures | Benjamin Price, Venture Manager, NOVA External Ventures Saint-Gobain | Suraj Kumar Rajwani, Co-Founder and Partner, DoubleRock Venture Capital | Ashley Ramirez, Investor & Chief of Staff, Halogen Ventures | Jeff Ransdell, General Partner, Rokk3r Fuel ExO | Wanda Reindorf, Managing Director, Clean Energy Venture Group | Alison Andrews Reyes, General Partner, 1843 Capital | Lisa Rhoads, Managing Director, Easton Capital Investment Group | Candace Richardson, Senior Associate, Town Hall Ventures | Mark Robinson, Founder and Managing Director, WAVE Equity Partners | Gus Roman, Venture Capital Associate, Global Founders Capital | Rob Rosenberg, Partner, Prolog Ventures | Brita Rosenheim, Partner, Better Food Ventures | Robert Rothman, Founder and Managing Member, InFocus Capital Partners | Tayo Sanders, Associate, Anzu Partners | Sugam Sarin, Investment Manager, American Express Ventures | Jennifer Schretter, Partner, PROOF VC | Brian Schuman, Associate Manager, PepsiCo Technology Ventures | Paul Seidler, Managing Director, Clean Energy Trust | Shantnu Sharma, Managing Director, AMD Ventures | Charles Sidman, Managing Partner, ECS Capital Partners | Jean Sini, Angel Investor | Matt Snow, Analyst, Greenspring Associates | Vivek Soni, Venture Partner, S Cap Cleantech Fund | Adarsh Sowcar, External Ventures Manager, NOVA External Ventures Saint-Gobain | Joseph Spivack, Angel Investor | Lindsay Karas Stencel, Managing Partner, Gravity Ventures | Lutz Stoeber, Investment Director, Evonik Venture Capital | Neil Swami, Principal, Catalyst Health Ventures | Byron Thom, Principal, Framework Venture Partners | Michael Thomas, Investment Director, Inova Health System Strategic Investments | Alexander Urban, Associate, Shell Ventures | Claude Vachet, Managing Partner, Cycle Capital Management | Erica Van, Investor, Charles River Ventures | Kutral Veerabadran, Principal, Flow Capital | Sonali Vijayavargiya, Managing Director, Augment Ventures | Patrick Walsh, Director, National Grid Partners | George Wang, Associate, Global Founders Capital | Raymond Wang, Investor, Two Sigma Ventures | John Wei, Senior Investment Manager, SABIC Ventures | Jeffrey Weiss, Senior Venture Partner, Clean Energy Ventures | Catherine Friend White, Managing Director, Golden Seeds | Henry White, Venture Partner, Good Growth Capital | Alex Whitney, Senior Analyst, ManchesterStory Group | Jacqueline Wibowo, Investor, Insight Partners | Tom Wisniewski, Co-Founder & Managing Partner, Newark Venture Partners | Joanne Wong, General Partner, REDDS Capital | Zac Yu, Investor, Magnet Ventures | Greg Zaic, Principal and General Partner, NMT Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Sebastian Zhou, Investor, Alpha Square Group | Chris Zock, Managing Director, Sandbox Insurtech Ventures and many more…

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence has made special arrangement for our network to receive $100 off the current rates.

This conference will be attended by the best people in the industry. Please register asap to avoid disappointment. 

 

Register Today & Save Click here.   (Use promo code “LPBI-VIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 150 Top Innovators will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for the Seed stage track.

 

We look forward to seeing you there. 

 

Leaders in Pharmaceutical Business Intelligence & youngStartup Ventures

@@@@@

Special discount offered   

Use discount code LPBI-VIP and receive 10% off the “early bird” rates.

 

Call for Top Innovators to present to leading Investors (details below).

 

New England Venture Summit

December 3rd & 4th 2019 | Hilton | Boston, Dedham

Where Innovation Meets Capital

 

 http://bit.ly/2M8rxzd

UPDATES

From: “Gil Garalnick [FinTrack Venture Summit]” <Gil@youngstartup.com>

Date: Monday, October 7, 2019 at 3:45 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: Industry Partnership Update: New England Venture Summit

 

Hi Aviva –

 

Pleased to share an updated list of over 100 VCs and Angels confirmed to speak.

 

Early bird rates end October 31st. Would it feasible to share an update with your network? I can send over updated copy.

 

Partial List of over 100 VCs & Angel Investors confirmed to speak and judge includes:

Anil Achyuta, Investment Director, TDK Ventures | Omair Ahmed, Associate, Echo Health Ventures | Mark Austin, Managing Director, Viridian Capital | Natalie Bartlett, Investor, General Catalyst | Ned Berman, Senior Associate, Samsung Catalyst Fund | Carsten Boers, Managing Partner, Rhapsody Venture Partners | Greg Bohlen, Managing Director, Union Grove Venture Partners | Caitlin Bolnick, Investor, OpenView Venture Partners | Eric Breese, Investment Manager, Evonik Venture Capital | Brendan Brits, Investor, Bertelsmann Digital Media Investments | Ciara Burnham, Partner, QED Investors | Daniel Burstein, Managing Partner, Millennium Technology Value Partners | Jeffrey Carter, General Partner, West Loop Ventures | Kathryn Cartini, Partner, Chloe Capital | Anup Chamrajnagar, Investor, Point72 Ventures | Sean Cheng, Investment Manager, Philips Ventures | Elizabeth Cho-Fertikh, Co-Founder & Managing Director, MEDA Angels | Andrew Clapp, Managing Director, CIG CAP | Iain Cooper, Manager Corporate Ventures, Schlumberger Technology Investments | Mark Cupta, Partner, Prelude Ventures | Kapil Desai, Vice President, Catalyst Investors | Damien Despinoy, Director, Energy Foundry | Dan Doble, Managing Director, SABIC Ventures | Jesse Draper, Founding Partner, Halogen Ventures | Tyler Durham, Principal, Schlumberger Technology Investments | Laura Easton, Analyst, Real Ventures | Jonathan Friedlander, Principal, Digitalis Ventures | Lisa Frusztajer, Lead Investor, Portfolia Enterprise Fund | Stan Fung, Managing Director, FarSight Ventures | Robert Garber, Partner, 7wire Ventures | Stephen Gilfus, Founder, Blackboard Inc. | Emilia Gonzalez, Principal, Joyance Ventures | Ajay Gopal, Founding Principal, Framework Venture Partners | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | Edward Greer, Corporate Technology Scout, Dow Ventures | Vicky Guo, Investment Director, Pearson Ventures | Brooke Hammer, Associate, F-Prime Capital | Jana Hanova, Director, Evok Innovations | Andrew Hartford, Managing Partner, Hartford Lab | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Kaitlyn Henry, Associate, OpenView Venture Partners | Jay Karandikar, Venture Partner, New Crop Capital | Madeline Keulen, Vice President, Victress Capital | Roman Kikta, Managing Partner & Founder, Mobility Ventures | Frank Klemens, Managing Director, DuPont Ventures | Diana Kontsevaia, Investor, Dell Technologies Capital | Ventures | Luda Kopeikina, Investment Director, DSM Venturing | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Logan Langberg, Principal, Imaginary Ventures | James Lee, Investment Associate Director, Photon Fund | Claire Leurent, Managing Director, Samsung Ventures | Darwin Ling, Founding General Partner, Good AI Capital | Jim Lockheed, Investment Associate, JetBlue Technology Ventures | Mary Long-Irwin, Executive Director, Northern Ontario Angels | Wasim Malik, Managing Partner, Iaso Ventures | Hollis McGuire, Director, Impact NH Fund | Sarah Millar, Associate, City Light Capital | Craig Mullett, Director, Angel Investor Forum | Jared Newman, Associate, Betawork Ventures | Clay Norris, Investment Associate, Carolinas Fintech Ventures | Mike Perry, Investment Associate, Link Ventures | Lauren Michelle Pfeifer, Principal, Maschmeyer Group Ventures | Jeff Ransdell, General Partner, Rokk3r Fuel ExO | Wanda Reindorf, Managing Director, Clean Energy Venture Group | Alison Andrews Reyes, General Partner, 1843 Capital | Lisa Rhoads, Managing Director, Easton Capital Investment Group | Mark Robinson, Founder and Managing Director, WAVE Equity Partners | Gus Roman, Venture Capital Associate, Global Founders Capital | Rob Rosenberg, Partner, Prolog Ventures | Tayo Sanders, Associate, Anzu Partners | Jennifer Schretter, Partner, PROOF VC | Reese Schroeder, Managing Director, Tyson Ventures | Paul Seidler, Managing Director, Clean Energy Trust | Shantnu Sharma, Managing Director, AMD Ventures | Jean Sini, Angel Investor | Vivek Soni, Venture Partner, S Cap Cleantech Fund | Joseph Spivack, Angel Investor | Alex Steiner, Investment Analyst, Anthemis Group | Lutz Stoeber, Investment Director, Evonik Venture Capital | Neil Swami, Principal, Catalyst Health Ventures | Alexander Urban, Associate, Shell Ventures | Claude Vachet, Managing Partner, Cycle Capital Management | Erica Van, Investor, Charles River Ventures | Patrick Walsh, Director, National Grid Partners | Raymond Wang, Investor, Two Sigma Ventures | Greg Zaic, Principal and General Partner, NMT Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Sebastian Zhou, Investor, Alpha Square Group | Chris Zock, Managing Director, Sandbox Insurtech Ventures and many more…

 

Look forward to hearing from you.

 

 

Regards

 

Gil

 

Gil Garalnick

Associate 
youngStartup Ventures
“Where Innovation Meets Capital”

 

p: 212.202.1002

e: gil@youngstartup.com

u: www.youngstartup.com

 

Friends,

 

Come meet, interact and network with hundreds of VCs, Corporate VCs, angel investors, investment bankers and founders of venture backed, emerging and early stage companies on the Lifesciences/Healthcare Track at the prestigious New England Venture Summit being held on December 3rd & 4th 2019 at the Hilton in Boston, Dedham.

 

Whether you’re a Lifescience/Healthcare startup seeking capital and exposure, or a Biotech investor seeking new deals, The New England Venture Summit presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, the Lifesciences/Healthcare track at The New England Venture Summit is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage companies.

 UPDATED on 8/27/2019

 

VCs & Angel Investors confirmed to speak and judge includes:

Mark Austin, Managing Director, Viridian Capital | Greg Bohlen, Managing Director, Union Grove Venture Partners | Ciara Burnham, Partner, QED Investors | Jeffrey Carter, General Partner, West Loop Ventures | Kathryn Cartini, Partner, Chloe Capital | Anup Chamrajnagar, Investor, Point72 Ventures | Andrew Clapp, Managing Director, CIG CAP | Iain Cooper, Manager Corporate Ventures, Schlumberger Technology Investments | Jesse Draper, Founding Partner, Halogen Ventures | Tyler Durham, Principal, Schlumberger Technology Investments | Robert Garber, Partner, 7wire Ventures | Stephen Gilfus, Founder, Blackboard Inc. | Emilia Gonzalez, Principal, Joyance Ventures | Ajay Gopal, Founding Principal, Framework Venture Partners | Michelle Gouveia, Associate, Sandbox Insurtech Ventures | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Kaitlyn Henry, Associate, OpenView Venture Partners | Jay Karandikar, Venture Partner, New Crop Capital | Roman Kikta, Managing Partner & Founder, Mobility Ventures | Elaine Kunda, Founder & Managing Director, Disruption Ventures | Darwin Ling, Founding General Partner, Good AI Capital | Sarah Millar, Associate, City Light Capital | Craig Mullett, Director, Angel Investor Forum | Jared Newman, Associate, Betawork Ventures | Lauren Michelle Pfeifer, Principal, Maschmeyer Group Ventures | Lisa Rhoads, Managing Director, Easton Capital Investment Group | Mark Robinson, Founder and Managing Director, WAVE Equity Partners | Tayo Sanders, Associate, Anzu Partners | Reese Schroeder, Managing Director, Tyson Ventures | Paul Seidler, Managing Director, Clean Energy Trust | Jean Sini, Angel Investor | Vivek Soni, Venture Partner, S Cap Cleantech Fund | Alex Steiner, Investment Analyst, Anthemis Group | Claude Vachet, Managing Partner, Cycle Capital Management | Erica Van, Investor, Charles River Ventures | Raymond Wang, Investor, Two Sigma Ventures | Greg Zaic, Principal and General Partner, NMT Capital | Lu Zhang, Founder & Managing Partner, Fusion Fund | Chris Zock, Managing Director, Sandbox Insurtech Ventures and many more…

 

Lineup of over 120 VCs & Angels that spoke and judged at NEVS18 includes:

Karine Agajanian, Analyst, Anzu Ventures | Sanjay Aggarwal, Venture Partner, F-Prime Capital Partners | Magdi Amin, Investment Partner, Omidyar Network | Peter Arkell, Investor, Norwest Venture Partners | Mark Austin, Partner, Bright Capital | Salman Azhar, Managing Director, Duke Angel Network | Ibraheem Badejo, Sr. Director, Johnson & Johnson Innovation | Sunny Bai, Associate, CRCM Ventures | Janet Bannister, Partner, Real Ventures | Peter Bastien, Partner, Next47 | Alex Beletsky, Investor, Sidecar Angels | Woody Benson, Venture Partner, Launch Capital | Joshua Berg, Investment Manager, GM Ventures | Raghav Bhargava, Associate, NEA | Victor Bian, Associate, Intellectual Ventures | Laura Bock, Investor, QED Investors | Nabil Borhanu, Managing Partner, Graphene Ventures | Will Borthwick, Senior Associate, Bold Capital Partners | Lee Bouyea, Managing Director, FreshTracks Capital | Eric Breese, Managing Director, Evonik Venture Capital | Maxx Bricklin, Founding Principal, Bold Capital Partners | Dan Burstein, Managing Partner, Millennium Technology Value Partners | Jason Cahill, Founder & Managing Director, McCune Capital | Neil Callahan, Co-Founder and Managing Director, Pilot Growth Equity | Efayomi Carr, Associate, Quona Capital | Sara Chamberlain, Managing Director, Energy Foundry | Raymond Chang, Managing Director, NXT Ventures | Christopher Chu, Managing Director, Samsung Catalyst Fund | Meghan Cross Breeden, Managing Partner, Red Bear Angels | David Cruikshank, Partner, ARCH Venture Partners | Sophia Dardashti, Associate, WorldQuant Ventures | Ekaterina Dorozhkina, Managing Partner, Starta Ventures | Miriam Eaves, Venture Partner, BP Ventures | Kathryn Meng Elmes, Investment Associate, Massachusetts Clean Energy Center | Alison Ernst, Senior Manager of Investments, Massachusetts Clean Energy Center | Teresa Esser, Managing Director, Silicon Pastures | Michael Fanfant, Investor, Runa Capital | David Feldman, Analyst, Indicator Ventures | Mark G. Fields, Partner, Alsop Louie Partners | Shawn Flynn, Investment Director, Bay Angels | Prashant Fonseka, Principal, Tuesday Capital | Haley Fradkin, Investment Associate, Plum Alley | Lisa Frusztajer, Investor, Portfolia Enterprise Fund | Kyle Fugere, Head of Ventures, dunnhumby Ventures | Matt Gatto, Partner, Insight Venture Partners | Joy Ghosh, Investor, Bain Capital Ventures | Stephen Gilfus, Founder, Blackboard Inc. | Jamil Goheer, Managing Partner & Cofounder, CoVenture | Ben Gorman, Associate, F-Prime Capital Partners | Edward Greer, Corporate Technology Scout, Dow Ventures | Jacob E. Grose, Investment Manager, BASF Venture Capital | Zain Gulamali, Investor, Amazon Alexa Fund | Marina Hadjipateras, Co-Founder & General Partner, Trail Mix Ventures | Hunter Hartwell, Principal, Forte Ventures | Laurence Hayward, Founding Partner, Independence Equity | Nathaniel Henshaw, Managing Director, CEI Ventures | Michael Hoeksema, Associate, Battery Ventures | Lindsay Hyde, Venture Partner, Moderne Ventures | Oren Isacoff, Principal, Longitude Capital | Nicolas Jacques-Bouchard, Principal, Panache Ventures | Jamie James, Managing Partner, GreenSoil Building Innovation Fund | Noel Jee, Investor, Illumina Ventures | Lacey Johnson, Principal, Green D Ventures | Ajay Kamat, Managing Director, Pear Ventures | Alex Kaufman, Investment Associate, JetBlue Technology Ventures | Shane Kelly, Head of Investments, CrowdSmart | Patrick Kenealy, Managing Director, Ridge Ventures | Jack Kerrigan, Managing Director, Razor’s Edge Ventures | Jonathan Kerstein, Associate, Red Sea Ventures | Nyla Koncurat, Managing Partner, Karlani Capital | Daniel Kwak, Investor, Point72 Ventures | Vivek Ladsariya, Partner, SineWave Ventures | Donna Lecky, Managing Director, Health Venture Capital | Linus Liang, Senior Associate, Signia Venture Partners | Bion Ludwig, Partner, Savano Capital Partners | Kyle Lui, Principal, DCM Ventures | Tamim Abdul Majid, Principal, OCA Ventures | Nurzhas Makishev, Managing Partner, NKM Capital | Eller Mallchok, Managing Director, Jumpstart Foundry | Coppelia Marincovic, Investment Manager, Solvay Ventures | Olga Maslikhova, Managing Partner, Phystech Ventures | Tom Mastrobuoni, Chief Financial Officer, Tyson Ventures | Hiroki Matsuda, Investor, Sozo Ventures | Derek Mazur, Senior Associate, Sante Ventures | David Miller, Co-Founder and Managing Director, Clean Energy Ventures | Julia Moore, Partner, Breakout Ventures | Kirsten Morbeck, Managing Director, SpringRock Ventures | Amit Mulgaonkar, Investor, Mithril Capital Management | Sheila Narayan, Managing Director, Golden Seeds | David Nault, General Partner, Luge Capital | Sara M. Nayeem, Partner, NEA | Brian Panoff, Senior Principal, Shell Ventures | Sumay Parikh, Principal, Quake Capital | Daniel Povitsky, Vice President, Sinai Ventures | Vinny Pujji, Investor, Insight Venture Partners | Venu Raghavan, Vice President, Wasson Enterprise | Gopal Rajaraman, Investment Principal , Motorola Solutions Venture Capital | Wanda Reindorf, Managing Director, Clean Energy Ventures | Brendan Rempel, Associate, OpenView Venture Partners | Martin Ringlein, Venture Partner, NextGen Venture Partners | Praveen Sahay, Managing Director, WAVE Equity Partners | Louis Schick, Founding Partner, NewWorld Capital Group | Chris Seitz, Associate, Excel Venture Management | Connie Sheng, Founding Managing Partner, Nautilus Venture Partners | Alex Shtarkman, Associate, Revolution | John Simon, Managing Director, Sigma Prime Ventures | Sidarth Singh, Investor, Stripes Group | Emily Snyder, Associate, Borealis Ventures | Vivek Soni, Managing Director, TiE-Boston Angels | Siri Srinivas, Associate, Draper Associates | Luisa Sucre, Associate, Revolution | Lyndsey Toeppen, Vice President, Sandbox Insurtech Ventures | Tibor Toth, Managing Director, Massachusetts Clean Energy Center | Laurel Touby, Partner, Supernode Ventures | Chisom Uche, Associate, SixThirty | Alexander Urban, Principal, Shell Ventures | Claude Vachet, Managing Partner, Cycle Capital Management | Maria Velissaris, Investor, Pipeline Angels | Anthony Walsh, Principal, BioInnovation Capital | John Wei, Sr. Investment Manager, SABIC Ventures | Jamie M. Weston, Managing Director, Spring Mountain Capital | Christopher J. Whalen, Managing Director, New Technology Ventures | Thomas Whiteaker, Partner, Propel Venture Partners | Jillian Williams, Investor, Anthemis Group | Troy Williams, Managing Director, University Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Sanjay Zimmermann, Associate, White Star Capital and many more.

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence (LPBI) Group has made special arrangement for our network to receive a special discount of 10% off the existing “early bird” savings.

This conference will be attended by the best people in the industry. Please register early to avoid disappointment. 

 

Register Today & Save Click here.   

(Use promo code “LPBI-VIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking. 

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators from the Life Sciences/Healthcare sector will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for our Seed stage track.

 

We look forward to seeing you there. 

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

&

youngStartup Ventures

 

REAL TIME Press Coverage for

 http://pharmaceuticalintelligence.com 

by

 Aviva Lev-Ari, PhD, RN

Director & Founder, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief, Open Access Online Scientific Journal, http://pharmaceuticalintelligence.com

Editor-in-Chief, BioMed e-Series, 16 Volumes in Medicine, https://pharmaceuticalintelligence.com/biomed-e-books/

@pharma_BI

@AVIVA1950

 #NEVS

 

Logo, Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Our BioMed e-series

WE ARE ON AMAZON.COM

https://lnkd.in/ekWGNqA

2019 New England Venture Summit, December 3rd & 4th 2019 at the Hilton in Boston, Dedham, MA, hosted by youngStartUp #NEVS

 

AGENDA

Wednesday, December 4th, 2019

8:00 am

CONFERENCE REGISTRATION & CONTINENTAL BREAKFAST

8:50 am

WELCOME REMARKS

9:00 am

THE CHANGING VENTURE WORLD: WHAT CAN WE EXPECT FOR THE NEXT 24 MONTHS?

Venture Capital thought leaders debate the challenges and opportunities facing Investors and Entrepreneurs

9:50 am

BREAK

10:00 am

COMPANY PRESENTATIONS – ROUND I

11:00 am

NETWORKING & REFRESHMENT BREAK

11:40 am

COMPANY PRESENTATIONS – ROUND II

12:50 pm

LUNCH & NETWORKING

1:00 pm

RAISING ANGEL MONEY – INFO & INSIGHTS FROM SEASONED INVESTORS

1:50 pm

COMPANY PRESENTATIONS – ROUND III

3:00 pm

FUNDABLE DEALS: MAKING VCs SIT UP AND TAKE NOTICE

Ideas are all well and good, but in order to attract capital they will need to be packaged and presented in a way that will entice investors and of course a SOLID business model.  This panel will discuss the skills required to make a highly effective pitch that will attract potential financiers and the types of deals investors want.

3:00 pm

ENERGIZING THE FLOW OF CLEAN-TECH DEALS

This session will discuss the trends in the financial markets and the future of venture capital investment in clean-tech.

3:00 pm

ABCs ON ED-TECH INNOVATION & FUNDING

Ed-tech Investors will take center stage to grade the Ed-tech sector and share insights on the trends they’re seeing.

3:50 pm

NETWORKING & REFRESHMENT BREAK

4:30 pm

THE ART OF NEGOTIATING TERMS SHEETS

Entrepreneurs who don’t prepare well for term-sheet negotiations may find themselves locked into an uncomfortable relationship with their VC for years to come.  Whether you’re looking for a first round or follow-up funding, attend this panel to learn what you should know about negotiating term sheets.

4:30 pm

CORPORATE VENTURE CAPITAL: WHAT YOU NEED TO KNOW

With a new flowering of startup innovation, many giants of industry have decided to enter or re-enter the world of VC. This session will explore the value-added investment approach of Corporate VCs and how it yields important dividends that are “beyond the bottom line,” both for the investor and for the startup.

5:20 pm

AWARDS & CLOSING REMARKS

5:30 pm

SUMMIT ADJOURNS

SPEAKERS

https://youngstartup.com/newengland2019/#speakers-sec

Read Full Post »


#NYVS19 #NewYorkVentureSummit July 9th – 10th, Where #innovation Meets #Capital #startups connect with over 150 #AwesomeVCs and #Angels. http://bit.ly/30E9ci5 $100 off with Discount Code: LPBIVIP

 

Special discount.  Use discount code “ LPBIVIP” and receive $100 off the current rates.

Registration closes July 3rd

 

Call for Top Lifesciences/Healthcare Innovators to present to leading Investors (details below).

 

New York

Venture Summit

July 9th & 10th 2019 | Convene | New York City

Where Innovation Meets Capital

Friends,

Leaders in Pharmaceutical Business Intelligence Group

&

youngStartup Ventures

 

 

Come meet, interact and network with hundreds of VCs, Corporate VCs, angel investors, investment bankers and founders of venture backed, emerging and early stage companies on the Dedicated Lifesciences/Healthcare Track at the prestigious New York Venture Summit being held on July 9th & 10th 2019 at Convene, New York City.

 

Whether you’re a Lifesciences/Healthcare  startup seeking capital and exposure, or an investor seeking new deals, The New York Venture Summit presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, The New York Venture Summit is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage Lifesciences/Healthcare companies.

 

Partial list of over 150 VCs and Angels confirmed to speak and judge includes:

Jenny Abramson, Founder & Managing Partner, Rethink Impact | Nick Adams, Managing Partner & Co-Founder, Differential Ventures | Karine Agajanian, Senior Analyst, Anzu Partners | Andrew Aldrich, Principal, American Family Ventures | Jay Amarasekera, Senior Technology Manager, SABIC Ventures | Mark Austin, Managing Director, Viridian Capital | Michael Baldwin, Senior Associate, Moderne Ventures | Natalie Bartlett, Investor, General Catalyst | Greg Bennett, Senior Associate, Kapor Capital | Liza Benson, Partner, Moderne Ventures | Lily Bernicker, Associate, Collaborative Fund | Eric Bielke, Investment Director, GE Ventures | Laura Bock, Investor, QED Investors | Eric Breese, Investment Manager, Evonik Venture Capital | Matt Brennan, Partner, General Catalyst Partners | Joel Brightfield, Principal, SixThirty | Ciara Burnham, Partner, QED Investors | Daniel Burstein, Managing Partner, Millennium Technology Value Partners | Don Burton, Founding & Managing Partner, LearnStart | Jason Cahill, Founder & Managing Director, Carbon Ventures | Alex Carusillo, Venture Associate, OCA Ventures | Ray Cheng, Partner, Millennium Technology Value Partners | Bryan Ciambella, Principal, B Capital Group | Benjamin Cukier, Founder, Centana Growth Partners | Soraya Darabi, General Partner, Trail Mix Ventures | Tyler Dean, Investor, Point72 Ventures | Parth Desai, Investor, Flare Capital Partners | Damien Despinoy, Director, Energy Foundry | Sohum Doshi, Associate, Argentum Group | Alan Du, Investor, Millennium Technology Value Partners | Tyler Durham, Principal, Schlumberger Ventures | Kenny Estes, Co-Founder & Partner, West Loop Ventures | Dave Fan, Principal, Alumni Ventures Group | Michael Fanfant, Senior Associate, Runa Capital | Matt Fates, Founder & General Partner, Pulse Ventures | Sana Fathima, Investment Manager, Lockheed Martin Ventures | Mark G. Fields, Partner, Alsop Louie Partners | Linda Fingerle, President and Managing Director, Tappan Hill Ventures | Lindsay Fitzgerald, Managing Director, American Express Ventures | Haley Fradkin, Investment Associate, Plum Alley Investments | Daniel Franke, Associate, M Ventures | Ben Freeberg, Senior Associate, Alpha Venture Partners | Kyle Fugere, Head of Ventures, dunnhumby Ventures | Alexander Galitsky, Co-Founder and Managing Partner, Almaz Capital | Anna Garcia, General Partner, Runway Venture Partners | Elaine Gilde, Board Member, New York Angels | Stephen Gilfus, Founder, Blackboard Inc. | Karim Gillani, General Partner, Luge Capital | Alex Goldberg, Managing Director, Canary Ventures | Samara Gordon, Senior Associate, Hyperplane Venture Capital | Edward Greer, Corporate Technology Scout, Dow Ventures | Amanda Groves, Partner, PLUS Capital | John Gu, Investor, Spring Mountain Capital | Whitney Haring-Smith, Managing Partner, Anzu Partners | Will Hawkins, Senior Associate, Founder Collective | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Diane Henry, Founder, Rogue Capital Collective | Cat Hernandez, Partner, Primary Venture Partners | Ann Hickey, Vice President, Town Hall Ventures | Kyle Howard-Johnson, Investor, Catalyst Investors | Vinay Iyengar, Investor, Bessemer Venture Partners | Deborah Jackson, Founder, Plum Alley Investments | Dhruv Jain, Investor, Bessemer Venture Partners | Christina Jenkins, Lead Investor, Portfolia | Del Johnson, Principal, Backstage Capital | Joseph Kao, Principal, Millennium Technology Value Partners | Jay Karandikar, Venture Partner, New Crop Capital | Hana Khosla, Investor, Activant Capital | Avery Klemmer, Investor, FirstMark Capital | Jak Knowles, Vice President Venture Investments, Leaps by Bayer | Steve Konsek, Program Director, National Science Foundation | George Krautzel, Managing Partner, MissionOG | Ricky Lai, Senior Associate, Portag3 Ventures | Eddie Lee, Senior Associate, White Star Capital | Oivind Lorentzen, Investor, Oak HC/FT | Marissa Lowman, Head of Education Practice, Village Capital | Bion Ludwig, Partner, Savano Capital Partners | Coppelia Marincovic, Investment Manager, Solvay Ventures | Elizabeth McCluskey, Principal, Impact Engine | Shripal Meghani, Partner, Cleveland Clinic Ventures | Arpesh Mehta, Investment Director, DSM Venturing | Andrée-Lise Méthot, Founder & Managing Partner, Cycle Capital Management | Ed Michael, Co-founder and Managing Partner, LionBird Ventures | Bá Minuzzi, General Partner, BABEL Ventures | Karolina Mrozkova, Associate, White Star Capital | Sonia Nagar, Partner, Pritzker Group Venture Capital | Greg Neufeld, Partner, ValueStream Ventures | Stuart O’Keeffe, Principal, Great Oaks Venture Capital | Jason Palmer, General Partner, New Markets Venture Partners | Victor Pascucci III, Managing Partner, Lightbank | Matt Perlman, Principal, IA Capital Group | Victoria Pettibone, Managing Director, Astia Angels | Daniel Pianko, Partner, University Ventures | Adam Plotkin, Partner, ff Venture Capital | Jean-Noel Poirier, Managing Partner, Clean Energy Venture Group | Bryan Rabenau, Principal, BP Ventures | Suraj Kumar Rajwani, General Partner, DoubleRock | K.P. Reddy, Founder, Shadow Ventures | Alison Andrews Reyes, General Partner, 1843 Capital | Lisa Rhoads, Managing Director, Easton Capital | Douglas Roth, Managing Director, Connecticut Innovations | Boris Ryabov, Managing Partner, Bright Capital | Ernst Sack, Partner, Blue Bear Capital | Praveen Sahay, Managing Director, WAVE Equity Partners | Zak Schwarzman, Partner, MetaProp | Thomas Seo, Vice President, Citi Ventures | Connie Sheng, Founding Managing Partner, Nautilus Venture Partners | Jaidev Shergill, Managing Partner, Capital One Growth Partners | Zacary Sherman, Associate, Pereg Ventures | Nicole Shimer, Investment Associate, Insight Partners | Bennett Siegel, Investor, Coatue Management | Raj Singh, Managing Partner, JetBlue Technology Ventures | Jean Sini, Angel Investor | Vivek Soni, Venture Partner, S Cap Cleantech Fund | Corinne Spears, Associate, University Ventures | Amit Srivastava, Senior Partner, Cycle Capital Management | Nico Stainfeld, Analyst, Citi Ventures | Lutz Stoeber, Investment Director, Evonik Venture Capital | Neil Swami, Principal, Catalyst Health Ventures | David Sym-Smith, Partner, Mobility Ventures | Nilay Thakar, Associate, ARCH Venture Partners | Chisom Uche, Senior Associate, SixThirty | Erica Van, Associate, Charles River Ventures | Maria Velissaris, Founding Partner, SteelSky Ventures | David Wadler, Vendorful, Co-founder and CEO | Patrick Walsh, Director, National Grid Partners | Jamie M. Weston, Managing Director, Spring Mountain Capital | Tom Wisniewski, Co-Founder & Managing Partner, Newark Venture Partners | Simon Wu, Principal, Cathay Innovation | Anthony Xu, Partner, New Ground Ventures | Lisa Xu, Investor, FirstMark Capital | Wesley Yiu, Senior Associate, Triphammer Ventures | Chris Young, Partner, Revel Partners | Greg Zaic, General Partner, NMT Capital | Katherine Zamsky, Managing Partner, Carbon Ventures | Stephanie Zepeda, Senior Associate, Arbor Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Chris Zock, Managing Director , Sandbox Insurtech Ventures and many more.

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence Group has made special arrangement for our network to

receive $100 off the current rates.

Registration closes July 3rd

This conference will be attended by the best people in the industry. Please register asap to avoid disappointment.

Register Today & Save Click here.   

(Use promo code “LPBIVIP”)

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking.

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators from the Technology, Life Sciences/Healthcare, CleanTech and Fintech sectors will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for our Seed stage track.

We look forward to seeing you there.

Leaders in Pharmaceutical Business Intelligence Group

&

youngStartup Ventures

 

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: June 4 Morning Sessions; Global Biotech Investment & Public-Private Partnerships

Reporter: Stephen J Williams PhD @StephenJWillia2

Each country have their own needs and most important drug cost structure. Must involve patients and providers.
BCI survey: countries output different, who improved who didnt
Is industry having collaboration with government? hardly ten percent by survey and worse vice versa
Transparancy and holistic view important for collaboration
Korea: lack of communication need input from government on pricing; wants global open innovation and enhance RD investments
Tawain: price, price but based on efficacy; pharma needs to talk with doctors hospital patients, find balance
Pitts: we need trust; staff that country offices with people who know that country. Price not defining value
Columbia:  need to attract investors

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: What’s Next: The Landscape of Innovation in 2019 and Beyond. 3-4 PM June 3 Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

 

Results from Clarivate
In 2018 most of deals were in CART area but now we are seeing more series A rounds that are on novel mechanisms as well as rare diseases.  US is still highest in venture capital series A but next is China. 10 of top ex US VC are from China, a whole lot of money.
Preclinical is very strong for US VC but China VC is focused on clinical.  First time this year we see US series A break above 100.  But ex US the series A is going down.  Although preclinical deals in US is coming back not like as good as in 2006.  But alot of > 1 billion $ deals.  Most of money into mAbs and protein therapy;  antisense is big and cell therapy is big too; small molecule not as much
ClearView Healthcare
Which innovation classes attracted VC in 2018?
  • Oncology drives a disproportionate focus could be driven by pharma focus on oncology; however there is some focus on neuro and infectious disease
  • therapeutic classes: shift to differentiated technology…. companies want technologic platforms not just drugs.  Nucleic Acid tech and antibody tech is high need platforms.  Startups can win by developing a strong platform not just a drug
There are pros and cons of developing a platform company versus a focused company.  Many VCs have a portfolio and want something to fit in so look for a focused company and may not want a platform company.  Pfizer feels that when alot of money is available (like now) platform investing is fine but when money becomes limited they will focus on those are what will be needed to fill therapy gaps.  They believe buy the therapy and only rent the platform.
Merck does feel the way Pfizer does but they have separate ventures so they can look and license platforms.  they are active in looking at companies with new modalities but they are focused on the money so they feel best kept in hands of biotech not pharma.
At Celgene they were solely focused on approvals not platforms.  Alot of money is required to get these platforms to market.  Concentration for platform companies should be the VCs not partnering or getting bought out by pharma.  it seems from panel speakers from pharma that they are waiting for science to prove itself and waiting for favorable monetary environments (easy money).  However it seems they (big pharma) are indicating that money is drying up or at least expect it too.
At Axial and with VCs they feel it is important to paint a picture or a vision at the early stage.
At Ontogeny, they focus on evaluating assets especially and most important, ThE MANAGEMENT TEAM.  There are not that many great talented drug development management teams he feels out there even though great science out there.

Read Full Post »


Real Time Coverage @BIOConvention #BIO2019: International Cancer Clusters Showcase June 3, Philadelphia PA

Reporter: Stephen J. Williams PhD @StephenJWillia2

 

Larry Blandford PharmD from Precision Medicine Group gave introduction about development of precision oncology medicine.  Talked about value and value determination for partnerships.

Company Pitches:

Kernal Biologics: Preclinical immunotherapy company developing mRNA therapeutics.  Their therapy only have activity in p53 deficient cells (messenger 2.0).  They identified, by screening, multiple mRNAs that have oncoselectivity; ONC-333 is their lead mRNA active in AML and NSCLC.  Looking for 5.5M seed $

Vaccibody AS: Vaccine technology from Oslo University to target antigen to antigen presenting cells.  They are targeting the myocytes and dimerize the antigen to MHC.  Targeting melanoma, certain cervical cancers, and hemotologic cancers.  Technology based on identified neoantigens obtained from tumor biopsy.Three vaccines: VB10.neo  VB10.16 against HPV cervical

Chimeric Therapeutics: developing CART to solid malignancies against CLEC14 (tumor endothelial marker), may make tumor susceptible to hypoxia.  Targeting pancreatic cancer, prelim results in mice , efficacy of 15%, working on 3rd generation CART

Memo Therapeutics: Antibody therapeutics; based on Dropzylla single B cell sorting and subsequent screening for mAb.  Targeting checkpoint inhibitors on solid tumors;  have a new target other than PD1; target undisclosed on NK cells and T cells; Early stage have academic partners; seeking 20Million Swiss Francs

Takeda Oncology: Chris Hurff Senior Director Business Development; they depend on partnerships as they feel internal RD is less effective.  They are diversifying their portfolio from small molecules. They have over 200 partnerships (132 in Boston). They are focusing on heme, lung, and Immunooncology. Partnering model: CEI (center external innovation) deals with both academic and small biotechs.  They have numerous partners including Shatto and MD Anderson.

 

 

Read Full Post »


Real Time Coverage of BIO 2019 International Convention, June 3-6, 2019 Philadelphia Convention Center, Philadelphia PA

Reporter: Stephen J. Williams, PhD @StephenJWillia2

Please follow LIVE on TWITTER using the following @ handles and # hashtags:

@Handles

@pharma_BI

@AVIVA1950

@BIOConvention

# Hashtags

#BIO2019 (official meeting hashtag)

Please check daily on this OPEN ACCESS JOURNAL for updates on one of the most important BIO Conferences of the year for meeting notes, posts, as well as occasional PODCASTS.

 

The BIO International Convention is the largest global event for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities, and provides insights and inspiration on the major trends affecting the industry. The event features keynotes and sessions from key policymakers, scientists, CEOs, and celebrities.  The Convention also features the BIO Business Forum (One-on-One Partnering), hundreds of sessions covering biotech trends, policy issues and technological innovations, and the world’s largest biotechnology exhibition – the BIO Exhibition.

The BIO International Convention is hosted by the Biotechnology Innovation Organization (BIO). BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products.

 

Keynote Speakers INCLUDE:

Fireside Chat with Margaret (Peggy) Hamburg, MD, Foreign Secretary, National Academy of Medicine; Chairman of the Board, American Association for the Advancement of Science

Tuesday Keynote: Siddhartha Mukherjee (Author of the bestsellers Emperor of All Maladies: A Biography of Cancer and  The Gene: An Intimate History)

Fireside Chat with Jeffrey Solomon, Chief Executive Officer, COWEN

Fireside Chat with Christi Shaw, Senior Vice President and President, Lilly BIO-Medicines, Eli Lilly and Company

Wednesday Keynote: Jamie Dimon (Chairman JP Morgan Chase)

Fireside Chat with Kenneth C. Frazier, Chairman of the Board and Chief Executive Officer, Merck & Co., Inc.

Fireside Chat: Understanding the Voices of Patients: Unique Perspectives on Healthcare

Fireside Chat: FDA Town Hall

 

ALSO SUPERSESSIONS including:

Super Session: What’s Next: The Landscape of Innovation in 2019 and Beyond

Super Session: Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Digital Health in Practice: A Conversation with Ameet Nathawani, Chief Digital Officer, Chief Medical Falling in Love with Science: Championing Science for Everyone, Everywhere

Super Session: Realizing the Promise of Gene Therapies for Patients Around the World

Super Session: Biotech’s Contribution to Innovation: Current and Future Drivers of Success

Super Session: The Art & Science of R&D Innovation and Productivity

Super Session: Dealmaker’s Intentions: 2019 Market Outlook

Super Session: The State of the Vaccine Industry: Stimulating Sustainable Growth

 

See here for full AGENDA

Link for Registration: https://convention.bio.org/register/

The BIO International Convention is literally where hundreds of deals and partnerships have been made over the years.

 

BIO performs many services for members, but none of them are more visible than the BIO International Convention. The BIO International Convention helps BIO fulfill its mission to help grow the global biotech industry. Profits from the BIO International Convention are returned to the biotechnology industry by supporting BIO programs and initiatives. BIO works throughout the year to create a policy environment that enables the industry to continue to fulfill its vision of bettering the world through biotechnology innovation.

The key benefits of attending the BIO International Convention are access to global biotech and pharma leaders via BIO One-on-One Partnering, exposure to industry though-leaders with over 1,500 education sessions at your fingertips, and unparalleled networking opportunities with 16,000+ attendees from 74 countries.

In addition, we produce BIOtechNOW, an online blog chronicling ‘innovations transforming our world’ and the BIO Newsletter, the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.

 

Membership with the Biotechnology Innovation Organization (BIO)

BIO has a diverse membership that is comprised of  companies from all facets of biotechnology. Corporate R&D members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. The majority of our members are small companies – 90 percent have annual revenues of $25 million or less, reflecting the broader biotechnology industry. Learn more about how you can save with BIO Membership.

BIO also represents academic centers, state and regional biotech associations and service providers to the industry, including financial and consulting firms.

  • 66% R&D-Intensive Companies *Of those: 89% have annual revenues under $25 million,  4% have annual revenues between $25 million and $1 billion, 7% have annual revenues over $1 billion.
  • 16% Nonprofit/Academic
  • 11% Service Providers
  • 7% State/International Affiliate Organizations

Other posts on LIVE CONFERENCE COVERAGE using Social Media on this OPEN ACCESS JOURNAL and OTHER Conferences Covered please see the following link at https://pharmaceuticalintelligence.com/press-coverage/

 

Notable Conferences Covered THIS YEAR INCLUDE: (see full list from 2013 at this link)

  • Koch Institute 2019 Immune Engineering Symposium, January 28-29, 2019, Kresge Auditorium, MIT

https://calendar.mit.edu/event/immune_engineering_symposium_2019#.XBrIDc9Kgcg

http://kochinstituteevents.cvent.com/events/koch-institute-2019-immune-engineering-symposium/event-summary-8d2098bb601a4654991060d59e92d7fe.aspx?dvce=1

 

  • 2019 MassBio’s Annual Meeting, State of Possible Conference ​, March 27 – 28, 2019, Royal Sonesta, Cambridge

http://files.massbio.org/file/MassBio-State-Of-Possible-Conference-Agenda-Feb-22-2019.pdf

 

  • World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON

https://worldmedicalinnovation.org/agenda-list/

https://worldmedicalinnovation.org/

 

  • 18th Annual 2019 BioIT, Conference & Expo, April 16-18, 2019, Boston, Seaport World Trade Center, Track 5 Next-Gen Sequencing Informatics – Advances in Large-Scale Computing

http://www.giiconference.com/chi653337/

https://pharmaceuticalintelligence.com/2019/04/22/18th-annual-2019-bioit-conference-expo-april-16-18-2019-boston-seaport-world-trade-center-track-5-next-gen-sequencing-informatics-advances-in-large-scale-computing/

 

  • Translating Genetics into Medicine, April 25, 2019, 8:30 AM – 6:00 PM, The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St Fl 40, New York

https://pharmaceuticalintelligence.com/2019/04/25/translating-genetics-into-medicine-april-25-2019-830-am-600-pm-the-new-york-academy-of-sciences-7-world-trade-center-250-greenwich-st-fl-40-new-york/

 

  • 13th Annual US-India BioPharma & Healthcare Summit, May 9, 2019, Marriott, Cambridge

https://pharmaceuticalintelligence.com/2019/04/30/13th-annual-biopharma-healthcare-summit-thursday-may-9-2019/

 

  • 2019 Petrie-Flom Center Annual Conference: Consuming Genetics: Ethical and Legal Considerations of New Technologies, May 17, 2019, Harvard Law School

http://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conference

https://pharmaceuticalintelligence.com/2019/01/11/2019-petrie-flom-center-annual-conference-consuming-genetics-ethical-and-legal-considerations-of-new-technologies/

 

  • 2019 Koch Institute Symposium – Machine Learning and Cancer, June 14, 2019, 8:00 AM-5:00 PM  ET MIT Kresge Auditorium, 48 Massachusetts Ave, Cambridge, MA

https://pharmaceuticalintelligence.com/2019/03/12/2019-koch-institute-symposium-machine-learning-and-cancer-june-14-2019-800-am-500-pmet-mit-kresge-auditorium-48-massachusetts-ave-cambridge-ma/

 

Read Full Post »


Leaders in Pharmaceutical Business Intelligence (LPBI) Group is pleased to announce its sponsorship and invite you to attend the Dedicated Lifesciences/Healthcare Track at New York Venture Summit presented by youngStartup Ventures.

 

 

 

Official Logo of Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

 

Special discount.  Use discount code LPBIVIP and receive 10% off the “early bird” rates. Early bird rates expire at the end of May.

 

>> Call for Top Lifesciences/Healthcare Innovators to present to leading Investors (details below).

 

New York

Venture Summit

July 9th & 10th 2019 | Convene | New York City

 

Where Innovation Meets Capital

 

 

Friends,

 

Come meet, interact and network with hundreds of VCs, Corporate VCs, angel investors, investment bankers and founders of venture backed, emerging and early stage companies on the Dedicated Lifesciences/Healthcare Track at the prestigious New York Venture Summit being held on July 9th & 10th 2019 at Convene, New York City.

 

Whether you’re a Lifesciences/Healthcare  startup seeking capital and exposure, or an investor seeking new deals, The New York Venture Summit presented by youngStartup Ventures – is the event of the year you won’t want to miss.

 

A highly productive venture conference, The New York Venture Summit is dedicated to showcasing VCs, Corporate VCs and angel investors committed to funding venture backed, emerging and early stage Lifesciences/Healthcare companies.

 

Partial list of VCs and Angels confirmed to speak and judge includes:

Jenny Abramson, Founder & Managing Partner, Rethink Impact | Nick Adams, Managing Partner & Co-Founder, Differential Ventures | Karine Agajanian, Senior Analyst, Anzu Partners | John Albright, Managing Partner, Relay Ventures | Andrew Aldrich, Principal, American Family Ventures | Liza Benson, Partner, Moderne Ventures | Lily Bernicker, Associate, Collaborative Fund | Laura Bock, Investor, QED Investors | Matt Brennan, Partner, General Catalyst Partners | Joel Brightfield, Principal, SixThirty | Ciara Burnham, Partner, QED Investors | Daniel Burstein, Managing Partner, Millennium Technology Value Partners | Don Burton, Founding & Managing Partner, LearnStart | Jason Cahill, Founder & Managing Director, McCune Capital | Alex Carusillo, Venture Associate, OCA Ventures | Benjamin Cukier, Founder, Centana Growth Partners | Ned Daoro, Senior Associate, Clocktower Technology Ventures | Soraya Darabi, General Partner, Trail Mix Ventures | Tyler Dean, Investor, Point72 Ventures | Parth Desai, Investor, Flare Capital Partners | Alan Du, Investor, Millennium Technology Value Partners | Tyler Durham, Principal, Schlumberger Ventures | Miriam Eaves, Venture Partner, BP Ventures | Kenny Estes, Co-Founder & Partner, West Loop Ventures | Dave Fan, Principal, Alumni Ventures Group | Michael Fanfant, Senior Associate, Runa Capital | Matt Fates, Founder & General Partner, Pulse Ventures | Sana Fathima, Investment Manager, Lockheed Martin Ventures | Lindsay Fitzgerald, Managing Director, American Express Ventures | Haley Fradkin, Investment Associate, Plum Alley Investments | Ben Freeberg, Senior Associate, Alpha Venture Partners | Kyle Fugere, Head of Ventures, dunnhumby Ventures | Anna Garcia, General Partner, Runway Venture Partners | Stephen Gilfus, Founder, Blackboard Inc. | Karim Gillani, General Partner, Luge Capital | Edward Greer, Corporate Technology Scout, Dow Ventures | John Gu, Investor, Spring Mountain Capital | Whitney Haring-Smith, Managing Partner, Anzu Partners | Will Hawkins, Senior Associate, Founder Collective | Martin Heidecker, Director, Investment Manager, Boehringer Ingelheim Venture Fund | Ann Hickey, Vice President, Town Hall Ventures | Kyle Howard-Johnson, Investor, Catalyst Investors | Vinay Iyengar, Investor, Bessemer Venture Partners | Deborah Jackson, Founder, Plum Alley Investments | Dhruv Jain, Investor, Bessemer Venture Partners | Del Johnson, Principal, Backstage Capital | Jay Karandikar, Venture Partner, New Crop Capital | Hana Khosla, Investor, Activant Capital | Avery Klemmer, Investor, FirstMark Capital | Jak Knowles, Vice President Venture Investments, Leaps by Bayer | Steve Konsek, Program Director, National Science Foundation | George Krautzel, Managing Partner, MissionOG | Ricky Lai, Senior Associate, Portag3 Ventures | Eddie Lee, Senior Associate, White Star Capital | Bion Ludwig, Partner, Savano Capital Partners | Coppelia Marincovic, Investment Manager, Solvay Ventures | Elizabeth McCluskey, Principal, Impact Engine | Shripal Meghani, Partner, Cleveland Clinic Ventures | Arpesh Mehta, Investment Director, DSM Venturing | Andrée-Lise Méthot, Founder & Managing Partner, Cycle Capital Management | Ed Michael, Co-founder and Managing Partner, LionBird Ventures | Sarah Millar, Associate, City Light Capital | Bá Minuzzi, General Partner, BABEL Ventures | Greg Neufeld, Partner, ValueStream Ventures | Jason Palmer, General Partner, New Markets Venture Partners | Matt Perlman, Principal, IA Capital Group | Victoria Pettibone, Managing Director, Astia Angels | Daniel Pianko, Partner, University Ventures | Adam Plotkin, Partner, ff Venture Capital | Jean-Noel Poirier, Managing Partner, Clean Energy Venture Group | Greg Pope, Principal, Anzu Partners | Alison Andrews Reyes, General Partner, 1843 Capital | Lisa Rhoads, Managing Director, Easton Capital | Douglas Roth, Managing Director, Connecticut Innovations | Boris Ryabov, Managing Partner, Bright Capital | Ernst Sack, Partner, Blue Bear Capital | Zak Schwarzman, Partner, MetaProp | Thomas Seo, Vice President, Citi Ventures | Connie Sheng, Founding Managing Partner, Nautilus Venture Partners | Jaidev Shergill, Managing Partner, Capital One Growth Partners | Zacary Sherman, Associate, Pereg Ventures | Nicole Shimer, Investment Associate, Insight Venture Partners | Raj Singh, Managing Partner, JetBlue Technology Ventures | Jean Sini, Angel Investor | Neil Swami, Principal, Catalyst Health Ventures | Erica Van, Associate, Charles River Ventures | Jamie M. Weston, Managing Director, Spring Mountain Capital | Anthony Xu, Partner, New Ground Ventures | Lisa Xu, Investor, FirstMark Capital | Wesley Yiu, Senior Associate, Triphammer Ventures | Chris Young, Partner, Revel Partners | Katherine Zamsky, Managing Partner, Carbon Ventures | Lu Zhang, Founder & Managing Partner, Fusion Fund | Greg Ziac, General Partner, NMT Capital | Chris Zock, Managing Director , Sandbox Insurtech Ventures and many more.

 

Special Offer:

Leaders in Pharmaceutical Business Intelligence Group has made special arrangement for our network to receive a special discount, currently 10% off the existing “early bird” savings. Early bird rates expire at the end of May.

This conference will be attended by the best people in the industry. Please register early to avoid disappointment. 

 

Register Today & Save Click here.   

(Use promo code “LPBIVIP”)

 

In addition to providing access to leading Investors, the conference will feature more than 100 pre-screened venture backed, emerging and early stage companies seeking capital, and hardcore networking. 

 

 

Call for TOP INNOVATORS!

Get Noticed > Get Funded > Grow Faster

 

A select group of more than 100 Top Innovators from the Technology, Life Sciences/Healthcare, CleanTech and Fintech sectors will be chosen to present their breakthrough investment opportunities to an exclusive audience of Venture Capitalists, Corporate Investors, Private Investors, Investment Bankers, and Strategic Partners.

 

Apply to Present / Nominate a company:

For more information or to be considered for one of the Top Innovator slots click here.

 

Seed Pitchfest:

If you are a seed stage company seeking angel funding of less than $1M (and have raised less than $300,000) click here to apply for our Seed stage track.

 

We look forward to seeing you there. 

 

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

&

youngStartup Ventures

Read Full Post »

Older Posts »